Results 11 to 20 of about 277,227 (258)

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Haematologica, 2016
Pomalidomide + low-dose dexamethasone is effective and well tolerated for refractory or relapsed and refractory multiple myeloma after bortezomib and lenalidomide failure.
Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H. Zaki, Jesus San Miguel   +22 more
doaj   +3 more sources

Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

Drug Design, Development and Therapy, 2016
Cody P Coyne,1 Lakshmi Narayanan2 1Department of Basic Sciences, 2Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Starkville, MS, USA Purpose: Corticosteroids are effective in the management of a variety ...
Coyne CP, Narayanan L
doaj   +1 more source

Lidocaine and Dexamethasone, Ketamine and Dexamethasone, and Dexamethasone Alone in Tonsillectomy Complications

Advanced Biomedical Research
Background: Common complications including stridor, laryngospasm, and bronchospasm are important in patients undergoing general anesthesia. Dexamethasone, lidocaine, and ketamine could have significant roles in reducing these complications. Here we aimed
Morteza Heidari, Hamidreza Shetebi, Parastoo Golshiri, Somayeh Hoghughi   +3 more
doaj   +2 more sources

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX [PDF]

, 2018
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/ dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the
Cochrane, T, Leiba, M, Joy Ho, P, San-Miguel, J, White, D, Kaufman, JL, Morton, J, Takezako, N, Belch, A, Cook, G, Dimopoulos, MA, Benboubker, L, Moreau, P, Kim, K, et al.   +14 more
core   +3 more sources

Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis

Frontiers in Medicine, 2022
BackgroundSevere COVID-19 pneumonia requiring intensive care treatment remains a clinical challenge to date. Dexamethasone was reported as a promising treatment option, leading to a reduction of mortality rates in severe COVID-19 disease.
Peter Jirak, Vincent van Almsick, Dimitrios Dimitroulis, Moritz Mirna, Clemens Seelmaier, Zornitsa Shomanova, Bernhard Wernly, Bernhard Wernly, Bernhard Wernly, Dilvin Semo, Daniel Dankl, Magdalena Mahringer, Michael Lichtenauer, Uta C. Hoppe, Holger Reinecke, Rudin Pistulli, Robert Larbig, Robert Larbig, Lukas J. Motloch   +18 more
doaj   +1 more source

Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis [PDF]

PeerJ
Objective This network meta-analysis evaluated the efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, with or without Dexamethasone (D), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic ...
Hongxia Xu, Jiankun Xing, Shaohui Yang, Lingyan Rong, Lingyan Liu, Xiaotao Chen   +5 more
doaj   +2 more sources

Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19

Frontiers in Immunology, 2023
IntroductionSevere COVID-19 is characterized by cytokine storm, an excessive production of proinflammatory cytokines that contributes to acute lung damage and death.
Ameet A. Chimote, Abdulaziz O. Alshwimi, Martina Chirra, Vaibhavkumar S. Gawali, Margaret V. Powers-Fletcher, Kristin M. Hudock, Kristin M. Hudock, Laura Conforti   +7 more
doaj   +1 more source

Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]

, 2012
Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos, Mayer, Wolfgang J., Wolf, Armin, Kook, Daniel, Ulbig, Michael, Reznicek, Lukas, Remy, Matthias, Kampik, Anselm   +7 more
core   +1 more source

Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.

PLoS ONE, 2019
IntroductionCombination therapy for acute lymphoblastic leukemia (ALL) is highly effective but results in significant toxicity including osteonecrosis.
Seth E Karol, Laura J Janke, John C Panetta, Laura B Ramsey, Xiangjun Cai, Monique A Payton, David A Jenkins, William E Evans, Mary V Relling   +8 more
doaj   +1 more source

Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2. [PDF]

PLoS ONE, 2015
UNLABELLED:We evaluated whether dexamethasone augments the osteogenic capability of bone marrow-derived stromal cells (BMSCs) and muscle tissue-derived stromal cells (MuSCs), both of which are thought to contribute to ectopic bone formation induced by ...
Masato Yuasa, Tsuyoshi Yamada, Takashi Taniyama, Tomokazu Masaoka, Wei Xuetao, Toshitaka Yoshii, Masaki Horie, Hiroaki Yasuda, Toshimasa Uemura, Atsushi Okawa, Shinichi Sotome   +10 more
doaj   +1 more source